Proficio Capital Partners LLC Acquires Shares of 30,717 Twist Bioscience Co. (NASDAQ:TWST)

Proficio Capital Partners LLC bought a new position in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 30,717 shares of the company's stock, valued at approximately $1,427,000. Proficio Capital Partners LLC owned approximately 0.05% of Twist Bioscience at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in TWST. Massachusetts Financial Services Co. MA increased its holdings in Twist Bioscience by 215.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company's stock valued at $1,324,000 after buying an additional 20,035 shares during the period. Barclays PLC increased its holdings in shares of Twist Bioscience by 214.8% in the 3rd quarter. Barclays PLC now owns 153,039 shares of the company's stock valued at $6,913,000 after acquiring an additional 104,420 shares during the period. FMR LLC increased its holdings in shares of Twist Bioscience by 6.0% in the 3rd quarter. FMR LLC now owns 218,561 shares of the company's stock valued at $9,875,000 after acquiring an additional 12,327 shares during the period. Avanza Fonder AB purchased a new stake in shares of Twist Bioscience during the 4th quarter worth $1,059,000. Finally, BNP Paribas Financial Markets boosted its position in Twist Bioscience by 128.1% during the third quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company's stock valued at $1,718,000 after purchasing an additional 21,357 shares in the last quarter.

Insider Buying and Selling at Twist Bioscience

In related news, insider Dennis Cho sold 806 shares of Twist Bioscience stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $49.35, for a total value of $39,776.10. Following the sale, the insider now directly owns 112,221 shares in the company, valued at approximately $5,538,106.35. The trade was a 0.71 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Paula Green sold 918 shares of the stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $40.91, for a total value of $37,555.38. Following the transaction, the senior vice president now directly owns 130,912 shares of the company's stock, valued at $5,355,609.92. The trade was a 0.70 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 33,845 shares of company stock valued at $1,603,945. Company insiders own 3.01% of the company's stock.

Remove Ads

Twist Bioscience Stock Performance

NASDAQ:TWST traded down $2.72 during mid-day trading on Monday, hitting $36.71. The company's stock had a trading volume of 1,733,475 shares, compared to its average volume of 985,475. The business's fifty day moving average is $46.54 and its two-hundred day moving average is $45.47. The stock has a market cap of $2.19 billion, a price-to-earnings ratio of -10.86 and a beta of 2.15. Twist Bioscience Co. has a 1 year low of $27.41 and a 1 year high of $60.90. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The business had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. During the same quarter in the prior year, the firm posted ($0.75) EPS. The business's quarterly revenue was up 24.1% compared to the same quarter last year. Analysts anticipate that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on TWST. Robert W. Baird increased their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a research report on Tuesday, February 4th. TD Cowen reissued a "buy" rating and set a $58.00 target price on shares of Twist Bioscience in a research report on Tuesday, November 26th. Scotiabank reaffirmed an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. Barclays set a $58.00 price objective on Twist Bioscience and gave the company an "overweight" rating in a report on Monday, February 3rd. Finally, Wolfe Research assumed coverage on Twist Bioscience in a research report on Friday, December 13th. They set an "outperform" rating and a $60.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $54.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.